Second-Hand Exposure of Staff Administering Vaporised Cannabinoid Products to Patients in a Hospital Setting.

Nadia Solowij Peter GalettisSamantha J BroydPeter de KreyJennifer H Martin

Published in: Drugs in R&D (2018)

These results are reassuring for hospital and clinical trial practices with staff administering vaporised cannabinoid products, and helpful to ethics committees wishing to quantify risk.

Keyphrases

clinical trial
healthcare
end stage renal disease
ejection fraction
chronic kidney disease
public health
acute care
adverse drug
peritoneal dialysis
emergency department
long term care
study protocol
patient reported